Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%
Market cap
$3.6B
P/E
29.9×
Fwd P/E
45.1×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
40.78 29.02 50.12 88.03

+8 more quarters

P/S ratio
8.36 4.73 6.40 5.46
P/FCF ratio
28.30 16.49 26.13 27.52
P/Operating CF
102.49 72.75 62.92 60.38
P/B ratio
3.38 1.91 2.53 2.15
Price to Tangible BV
8.72 5.21 7.30 6.79
EV/Sales
7.50 3.92 5.60 4.72
EV/EBITDA
34.00 22.14 38.17 52.96
EV/Operating CF
23.62 12.79 21.26 21.60
EV/FCF
25.39 13.68 22.88 23.81
Quick Ratio
8.60 8.72 7.63 5.74
Current Ratio
9.16 9.31 8.15 6.23
Net Debt/EBITDA
(17.91) (15.99) (9.87) (13.31)
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.40 0.39 0.38 0.37
Operating CF/Net income
1.80 1.23 1.28 2.34
Capex/Depreciation
(0.69) (0.61) (0.81) (0.61)
Research and Development Expense of Revenue
19.59% 19.49% 14.82% 12.12%
Selling, General and Administrative Expense of Revenue
37.06% 36.55% 30.79% 39.23%
Intangible Assets out of Total Assets
0.57 0.59 0.61 0.63
Share Based Compensation of Revenue
9.37% 9.18% 7.75% 8.16%
Graham Net Nets
0.10 0.17 0.12 0.13
Graham Number
23.72 20.55 17.75 11.84
Earnings Yield
2.45% 3.45% 2.00% 1.14%
Free Cash Flow Yield
3.53% 6.06% 3.83% 3.63%
Revenue per Share
1.88 1.75 1.79 1.68
Operating CF per Share
0.57 0.44 0.67 0.57
Capex per Share
(0.04) (0.04) (0.05) (0.04)
Free Cash Flow per Share
0.54 0.41 0.62 0.53
Cash per Share
6.07 5.52 5.25 4.65
Shareholders Equity per Share
17.36 16.90 16.66 15.98
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
17.36 16.90 16.66 15.98
Free Cash Flow
42.97 32.25 48.80 41.97
Working Capital
512.04 466.06 428.44 377.07
Capital Expenditures
(2.86) (2.96) (3.78) (2.79)
Net Current Asset Value
476.81 430.18 391.93 339.10
EV/EBIT
39.84 27.41 50.15 94.46
Capex to Sales
0.02 0.02 0.03 0.02
Price to Operating Income
44.41 33.05 57.26 109.17
Other line items
Average Receivables
52.50 51.95 45.59 48.32
Average Payables
9.74 11.31 6.61 7.59
Average Inventory
23.84 22.84 21.15 20.35
Average Assets
1,415.24 1,375.91 1,353.03 1,321.40
Average Common Equity
1,304.73 1,269.67 1,242.77 1,216.85

Fold the line items

Columns are period end dates